CURRICULUM VITAE
FOR
DONALD BOOS, MD
University of Virginia Health Systems
Dept. of Anesthesiology PO Box 800710
Charlottesville, VA 22908 Anesthesiology Residency 1986-1989
St. Vincent's Charity Hospital (formerly St. Luke's Hospital) 2351 E. 22" Street
Cleveland, 0H 44115
Internship
1985-1986
Medical College of Ohio
3045 Arlington Ave.
Toledo, OH 43614
MD. 1985
Cleveland State University 2121 Euclid Ave.
Cleveland, 0H 44115
MS Chemistry
1981
The University of Toledo 401 Jefferson Ave.
Toledo, OH 43601
BS Chemistry
1980
PROFESSIONAL EXPERIENCE:
Hot Springs Pain Clinic
One Mercy Lane, Suite 304
Hot Springs, AR 71913
1994-present
Little Rock Pain Clinic
2 Lile Ct., Suite 100
Little Rock, AR 72205-6241 1994
Meridian Anesthesia Group
1214 23rd Avenue
Meridian, MS 39301
1993-1994
Capitol Anesthesia
600 South McKinley, Suite 401 Little Rock, AR 72205
1992-1993
Keesler Medical Center
Assistant Director of Anesthesia Keesler Air Force Base
Biloxi, MS 39530
1989-1992
MEDICAL CERTIFICATIONS AND MEMBERSHIPS:
Diplomate, American Board of Anesthesiology
Diplomate, American Board of Pain Medicine
American Board of Anesthesiology: Added Qualifications in Pain Arkansas Medical Society
Southern Pain Society
International Spinal Injection Society
American Society of Regional Anesthesia
American Society of Interventional Pain Physicians
RESEARCH AFFILIATION:
Burke Pharmaceutical Research
3633 Central Avenue, Ste. I
Hot Springs, AR 71913
CLINICAL RESEARCH EXPERIENCE:
Sub-Investigator:
A Double-Blind, Randomized, Placebo Controlled, Parallel Group Outcomes Study In Persistent Back Pain Comparing Oxycontin Q12H vs. Placebo
Sub-Investigator:
A Three-Year, Open Label, Analgesic Efficacy, Safety Acceptability, Tolerability, and Quality of Life Registry of Controlled Release Oxycodone Tablets (Oxycontin) in Chronic Non-Cancer Pain
Sub-Investigator:
Morphine with Dextromethorphan: Conversion from other Opioid Analgesics
Sub-Investigator:
A Two-Year, Open Label Extension: Morphine with Dextromethorphan: Conversion from other Opioid Analgesics
Sub-Investigator:
Open Label, Sequential Crossover Evaluation of the Analgesic Dose Equivalence, Efficacy and Safety of Controlled Release Oxymorphone (Numorphan CR), Relative to Controlled Release Oxycodone (Oxycontin) and Controlled Release Morphine (MS Contin) in Patients with Cancer Pain
Sub-Investigator:
A Multicenter, Open Label Extension Study to Evaluate the Long-Term Safety and Effectiveness of Numorphan CR in Patients with Chronic Pain
Sub-Investigator:
A Double Blind, Randomized, Parallel-Arm, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Hydromorphone Hydrochloride Controlled-Release Compared to Placebo in Treating Moderate to Severe Pain in Patients with Osteoarthritis
Sub-Investigator:
A Phase 3, Randomized, Double-Blind, Dose-Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of a Single Epidural Dose of Sustained-Release Encapsulated Morphine (SKY0401) in the Management of Post-Operative Pain in Patients Undergoing Hip Arthroplasty
Sub-Investigator:
KRONUS-MSP Trial Kadian Effectiveness and Tolerability in a Demographically Diverse, Community-based Population
Sub-Investigator:
CTR1476G2304 Multicenter, double-blind, randomized, placebo-control, parallel-group study to evaluate the safety and efficacy of Trileptal in patients with neuropathic pain due to rad i cul opathy
Principal Investigator:
A Randomized, Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib (SC-65873) 40mg bid Add-On Therapy to Opioid Medication in Patients with Chronic Cancer Pain
Sub-Investigator:
An Open-Label, Long-Term Safety and Tolerability Study of Ziconotide Administered Intrathecally to Patients with Chronic Severe Pain
Principal Investigator:
An Open, Randomized, Parallel-Group, Multicenter Trial to Compare a Stratified Care Treatment Regimen based on Migraine Disability (MIDAS grade) versus Standard Therapy for the Acute Treatment of Migraine Headache
Principal Investigator:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of a Single Epidural Dose of Sustained-Release Encapsulated Morphine (SKY0401) in the Management of Post-Operative Pain in Patients Undergoing Lower Abdominal Surgery
Sub-Investigator:
A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Study of the Reversal of Opioid-Induced Gastrointestinal Dysfunction in Subjects Receiving Chronic Opioid Therapy for Pain or Opioid Addiction.
Sub-Investigator:
Dose Escalation of Morphidex versus Morphine in Opioid-Responsive Chronic Pain Patients
Sub-Investigator:
"Open-Label Extension of Morphidex Use in Chronic Pain Patients"
Sub-Investigator:
Grunenthal KF5503/09 A Randomized, Multicenter, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, Multiple-dose, Phase III b Study to Assess the Efficacy and Safety of CG5503 SR (24 mg, 50 mg, 100 mg; twice daily) in Comparison to Oxycodone CR 20 mg twice daily in Patients with Chronic Hip or Knee joint Osteoarthritis.
Principal Investigator:
Clinical Protocol for a Double-Blind Multicenter Study of the Safety and Efficacy of Parecoxib Followed by Valdecoxib Compared to Placebo in General Surgery Patients for Treatment of Post-Surgical Pain
Prinicipal Investigator:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects with Peripheral Neuropathic Pain
Sub-Investigator:
Purdue Pharma, BUP3018 A Randomized, Double-Blind Study Evaluating the Dose Conversion From Vicodin to Buprenorphine Transdermal System (BTDS) in Subjects with Osteoarthritis (OA) Pain.
Sub-Investigator:
Purdue Pharma BUP3019 Randomized, Double-Blind, Multicenter, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR versus BTDS 5 in Subjects with Moderate to Severe Osteoarthritis (OA) Pain.
Sub-Investigator:
Purdue Pharma I3UP3015 – A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR versus BTDS 5 in Subjects with Moderate to Severe Low Back Pain
Sub- Investigator:
CIMA Labs 099-14 – A Multicenter, Double-Blind, Placebo-Controlled Study of OraVescent Fenanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients
Sub- Investigator:
Cephalon, Inc. 099-15 – A Multicenter, Open-Label, Long-Term Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients
PRESENTATIONS:
1998: St. Joseph's Regional Health Center: Pain Seminar
1998: Cancer Committee: Pain Management in the Cancer Patient
1999: Arkansas Society of Transcriptionists: Common procedures in Pain Management 2000: Lupus Foundation: Pain Management for Lupus
